Metals in Urine and Peripheral Arterial Disease by Navas-Acien, Ana et al.
164 VOLUME 113 | NUMBER 2 | February 2005 • Environmental Health Perspectives
Research | Article
Peripheral arterial disease (PAD) is a conse-
quence of atherosclerotic occlusion of blood
flow in the muscular arteries of the lower
extremities. Because traditional risk factors
for atherosclerosis, such as age, smoking,
hypertension, and diabetes, do not com-
pletely explain the distribution of PAD in the
population, there is considerable interest in
identifying novel, nontraditional risk factors.
Certain metals may promote atherosclerosis
by increasing oxidative stress [e.g., by catalyz-
ing the production of reactive oxygen species
or inhibiting their degradation (Stohs and
Bagchi 1995)] or by affecting other cardio-
vascular risk factors [e.g., by increasing blood
pressure levels (Nawrot et al. 2002; Revis
et al. 1981)]. Arsenic, for instance, has been
associated with PAD and with other forms of
atherosclerosis in populations exposed to
arsenic in drinking water (Carter et al. 2003;
National Research Council 1999). However,
evidence for an association between most
metals and PAD is limited.
Blood cadmium and lead, at levels well
below current safety standards, were associated
with an increased prevalence of PAD in the
1999–2000 National Health and Nutrition
Examination Survey (NHANES) (Navas-Acien
et al. 2004). Cadmium and lead have been
associated with other cardiovascular end points,
such as myocardial infarction and stroke, in
some studies (Lustberg and Silbergeld 2002;
Ponteva et al. 1979) but not all (Pocock et al.
1988; Staessen et al. 1996). For several other
metals, including barium, cobalt, molyb-
denum, antimony, and thallium, data on their
role in human atherosclerosis are sparse
(Brenniman et al. 1979; Guo et al. 1992; Heim
et al. 2002; Schnorr et al. 1995). There are no
epidemiologic data on the potential cardio-
vascular effects of cesium or tungsten.
The objective of this study was to evaluate
the association of metal levels in urine with the
prevalence of PAD in NHANES 1999–2000,
a representative sample of the civilian, nonin-
stitutionalized U.S. population. In epidemio-
logic studies, PAD is usually defined by
the presence of a low (< 0.9) blood pressure
ankle-brachial index (ABI)—that is, when the
systolic blood pressure measured at the ankle
is < 90% of the systolic blood pressure meas-
ured at the arm (Selvin and Erlinger 2004).
We hypothesized that cadmium and lead
would be positively associated with PAD, as
determined by an ABI < 0.9. In addition, we
explored the association of PAD with urinary
barium, cobalt, cesium, molybdenum, anti-
mony, thallium, and tungsten, without prior
hypotheses. These metals were selected for
study in NHANES 1999–2000 by the
National Center for Health Statistics (NCHS).
The widespread exposure to these metals in
the general population [National Center for
Environmental Health (NCEH) 2003] and
the lack of relevant population data for most
of them underscore the public health rele-
vance of this study.
Materials and Methods
Study population. The NCHS has conducted
a series of cross-sectional health and nutrition
surveys beginning in the 1960s. These surveys
have used a stratified, multistage probability
cluster design to provide data representing the
noninstitutionalized U.S. population (NCHS
2004a). In 1999, NHANES became a contin-
uous survey and also began collecting infor-
mation on ABI in men and women ≥ 40 years
of age (NCHS 2004b).
Among the 9,965 participants in
NHANES 1999–2000, one-third of the study
population ≥ 6 years of age were randomly
selected to obtain urinary measurements of
metals (n = 2,465). NHANES 1999–2000
included a detailed lower-extremity exami-
nation that involved ABI measurements in
subjects ≥ 40 years of age with no bilateral
amputations and weighing < 400 lb (n = 2,875,
of whom 796 had a determination of urinary
metals). From these 796 participants, we
excluded one participant with an ABI value
> 1.5 [usually related to noncompressible ves-
sels in the legs (Newman et al. 1993)] and ﬁve
participants with no information on smoking
status or urine levels of creatinine, for a ﬁnal
sample size of 790 participants. A few remain-
ing participants had missing data for some of
the metals (sample size available for each metal
shown in Table 1). The response rate for the
household interview and the physical exam
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Exposure to metals may promote atherosclerosis. Blood cadmium and lead were associated with
peripheral arterial disease (PAD) in the 1999–2000 National Health and Nutrition Examination
Survey (NHANES). In the present study we evaluated the association between urinary levels of cad-
mium, lead, barium, cobalt, cesium, molybdenum, antimony, thallium, and tungsten with PAD in
a cross-sectional analysis of 790 participants ≥ 40 years of age in NHANES 1999–2000. PAD was
deﬁned as a blood pressure ankle brachial index < 0.9 in at least one leg. Metals were measured in
casual (spot) urine specimens by inductively coupled plasma–mass spectrometry. After multi-
variable adjustment, subjects with PAD had 36% higher levels of cadmium in urine and 49%
higher levels of tungsten compared with noncases. The adjusted odds ratio for PAD comparing the
75th to the 25th percentile of the cadmium distribution was 3.05 [95% conﬁdence interval (CI),
0.97 to 9.58]; that for tungsten was 2.25 (95% CI, 0.97 to 5.24). PAD risk increased sharply at low
levels of antimony and remained elevated beyond 0.1 µg/L. PAD was not associated with other
metals. In conclusion, urinary cadmium, tungsten, and possibly antimony were associated with
PAD in a representative sample of the U.S. population. For cadmium, these results strengthen pre-
vious ﬁndings using blood cadmium as a biomarker, and they support its role in atherosclerosis. For
tungsten and antimony, these results need to be interpreted cautiously in the context of an
exploratory analysis but deserve further study. Other metals in urine were not associated with PAD
at the levels found in the general population. Key words: antimony, atherosclerosis, cadmium, lead,
metals, peripheral arterial disease, tungsten. Environ Health Perspect 113:164–169 (2005).
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and 76%, respectively (NCHS 2004b).
PAD. A speciﬁc protocol was used to meas-
ure ABI in NHANES 1999–2000 (NCHS
2004b). The measurements of blood pressure
used for ABI were different from the measure-
ments of blood pressure used to deﬁne hyper-
tension. Supine systolic blood pressure was
measured on the right arm (brachial artery) and
both ankles (posterior tibial arteries) using a
Doppler device, the Parks Mini-Lab IV, model
3100 (Parks Medical Electronics, Aloha, OR,
USA). If the participant had a condition that
would interfere with blood pressure reading in
the right arm, the left arm was used. Systolic
blood pressure was measured twice at each
site for participants 40–59 years of age and
once at each site for participants ≥ 60 years of
age. The measurements for left and right ABI
were obtained by dividing the mean ankle sys-
tolic blood pressure in each side by the mean
brachial systolic blood pressure. PAD was
deﬁned as an ABI value < 0.90 in at least one
leg (Newman et al. 1993).
Urinary metals. A casual (or spot) urine
specimen was collected from the participants
after conﬁrmation of no background contami-
nation in collection materials (NCHS 2004b).
Urinary levels of cadmium, lead, barium,
beryllium, cobalt, cesium, molybdenum,
platinum, antimony, thallium, and tungsten
were measured at the Environmental Health
Sciences Laboratory of the Centers for Disease
Control and Prevention (CDC) and the
National Center for Environmental Health
(NCEH) by inductively coupled plasma–mass
spectrometry (PerkinElmer/SCIEX model
500; PerkinElmer, Shelton, CT, USA) using a
multielement analytical technique following
published protocols (NCHS 2004c; Paschal et
al. 1998). Cadmium levels in urine were cor-
rected for interference from molybdenum
oxide (NCHS 2004c). Urine Standard
Reference Material 2670 from the National
Institute of Standards and Technology
(Gaithersburg, MD, USA) was used for exter-
nal calibration and spiked pools prepared at
the laboratory were used for internal quality
control. Quality control samples included
both bench and blind samples. The ranges for
the interassay coefﬁcients of variation for each
metal are shown in Table 1. The limits of
detection varied by metal, from 0.01 µg/L
for thallium to 0.85 µg/L for molybdenum
(Table 1). The levels of beryllium and plati-
num were below the limit of detection in
> 98% of participants and were not consid-
ered further. For the other metals, the per-
centage of subjects with levels below the limit
of detection ranged from 0.5% for cesium to
30% for tungsten (Table 1). A level equal to
the limit of detection divided by the square
root of 2 was imputed for those subjects with
levels below the limits of detection.
Other variables. Information on age, sex,
race/ethnicity, education, and smoking was
based on self-report. Urinary creatinine was
determined using an enzymatic reaction meas-
ured with a CX3 analyzer (NCHS 2004b).
Statistical analysis. All statistical analyses
were performed using SUDAAN software
(Research Triangle Institute, Research Triangle
Park, NC, USA) to account for the complex
sampling design and weights in the NHANES
1999–2000 metal subsample. The jackknife
“leave-one-out” method was used to obtain
appropriate standard errors of all estimates.
Urinary metal levels were right skewed
and were log-transformed to improve normal-
ity. For each metal, the ratio of the geometric
mean urinary level and its 95% confidence
interval (CI) comparing subjects with PAD
versus subjects without PAD were estimated
using linear regression models on log-trans-
formed metal levels. For risk analyses, logistic
regression was used to obtain the adjusted
odds ratios and 95% CIs of PAD comparing
the 75th with the 25th percentile of the dis-
tribution of each metal assuming a log-linear
relationship between urinary metals and
PAD. We also used restricted cubic spline
transformations to assess nonlinear relation-
ships. All models were adjusted for age, sex,
race, and education level. In addition, we
evaluated the impact of further adjusting for
smoking status, a source of cadmium, lead,
and cobalt (International Agency for Research
on Cancer 1986). Metal levels were based in
one casual urine sample and thus depend on
urine dilution. Urinary metal levels were
adjusted for urinary creatinine to correct for
differences in urine dilution in spot urine
samples, but because of the limitations of
creatinine concentration to adjust for urine
dilution (Ikeda et al. 2003), we present results
both with and without creatinine adjustment.
We also repeated the analyses excluding sub-
jects fasting < 8 hr to evaluate the impact of
postprandial or fasting state and rapid renal
clearance of some metals. No substantial
changes were observed (data not shown). We
also assessed confounding by other cardio-
vascular risk factors, including hypertension,
hypercholesterolemia, diabetes, estimated
glomerular ﬁltration rate (Coresh et al. 2002),
and C-reactive protein, by adding them one
at a time to the multivariable models. No
noticeable changes were observed (data not
shown), and because of the limited sample
size, these additional variables were not
included in the ﬁnal models.
Results
Metal levels in urine. Table 1 describes urinary
metal levels in the study sample. The geo-
metric means were lowest for tungsten, 0.07
µg/L, and highest for molybdenum, 37.7 µg/L.
The median level and the interquartile range
for each metal by participant characteristics
are shown in Figure 1. Men had higher lev-
els than women for most metals, and cad-
mium and lead tended to increase with age.
Compared with whites, blacks and Mexican
Americans had higher levels of cadmium,
lead, and tungsten, and blacks had higher lev-
els of cesium, molybdenum, antimony, and
thallium. Current smokers had higher levels of
cadmium, lead, antimony, and tungsten com-
pared with never smokers.
Metals and PAD. The overall prevalence of
PAD in the study sample was 5.4% (54 cases).
After adjusting for demographic variables,
smoking status, and creatinine in urine, subjects
with PAD had 36% (95% CI, 1 to 83) higher
mean levels of cadmium in urine compared
with subjects without PAD (Table 2). Levels of
lead, barium, cobalt, cesium, molybdenum,
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Table 1. Metal levels (µg/L) in urine.
Cadmium Lead Barium Cobalt Cesium Molybdenum Antimony Thallium Tungsten
Sample size 728 790 704 790 790 728 725 776 751
Geometric mean 0.36 0.79 1.28 0.31 4.09 37.7 0.11 0.16 0.07
Percentile
10th 0.10 0.20 0.30 0.10 1.50 11.0 < LOD 0.06 < LOD
25th 0.19 0.50 0.70 0.18 2.80 21.2 0.07 0.10 < LOD
50th 0.36 0.90 1.40 0.33 4.50 41.2 0.11 0.18 0.06
75th 0.67 1.50 2.60 0.53 6.80 71.3 0.17 0.26 0.13
90th 1.16 2.30 4.70 0.81 9.40 126.1 0.29 0.38 0.26
Maximum 12.8 31.5 42.2 556.6 67.4 683.5 5.70 0.86 4.74
LOD 0.06 0.10 0.08 0.07 0.10 0.85 0.04 0.01 0.04
Percent < LOD 1.5 1.8 3.3 3.4 0.5 0.6 9.0 1.3 30.0
Range of CV (%) 1.2–4.7 1.0–5.3 1.4–6.2 1.8–6.0 1.5–9.2 0.6–5.6 1.3–4.8 1.2–8.5 1.1–2.8
Abbreviations: CV, coefﬁcient of variation; LOD, limit of detection.antimony, and thallium were similar in subjects
with and without PAD. Subjects with PAD
had 49% (95% CI, –10 to 249) higher mean
levels of tungsten. The association of cadmium
and tungsten with PAD was also evident in
logistic models (Table 3, Figure 2). The odds
ratio for PAD comparing the 75th with the
25th percentile of the cadmium distribution
was 3.05 (95% CI, 0.97 to 9.58). The corre-
sponding odds ratio for tungsten was 2.25
(95% CI, 0.97 to 5.24). For antimony, no asso-
ciation was apparent in linear models (Tables 2
and 3), but nonlinear models showed an
increase in the prevalence of PAD at very low
levels and a plateau of risk > 0.1 µg/L (Figure 2).
Discussion
Cadmium. Cadmium levels in urine were
36% higher in subjects with PAD than in
those without PAD. This association was simi-
lar but actually stronger than the previously
reported association between blood cadmium
and PAD in NHANES 1999–2000, where
blood cadmium was 16% higher in PAD cases
than in noncases (Navas-Acien et al. 2004).
The stronger association for urinary compared
with blood cadmium probably reﬂects the fact
that urinary cadmium is a more reliable bio-
marker of chronic cadmium exposure than
blood cadmium (ATSDR 1999a; Trzcinka-
Ochocka et al. 2004). The association between
cadmium levels and PAD was not explained by
smoking status, and adjusting for smoking
decreased only slightly the magnitude of the
association. In our study, an increased preva-
lence of PAD was associated with low levels of
urinary cadmium, below the levels reported in
workers exposed to cadmium occupationally
(Olsson et al. 2002). For example, only two
subjects had cadmium levels > 3 µg/g of creati-
nine, the Occupational Safety and Health
Administration safety standard for cadmium
in urine (Occupational Safety and Health
Administration 2003). In the NHANES popu-
lation, because occupational exposure is
expected to be relatively rare, it is likely that
exposure to cadmium occurred mainly through
cigarette smoking, inhalation of airborne
cadmium in ambient air (usually higher near
coal-fired power plants and municipal waste
incinerators), or consumption of some foods
(highest levels in shellfish, liver, and kidney
meats) (ATSDR 1999b).
Several mechanisms may explain an
increased risk of atherosclerosis with cadmium,
including the catalysis of reactive oxygen
species (Stohs and Bagchi 1995; Vaziri et al.
2001), the promotion of lipid peroxidation
(Ding et al. 2000; Yiin et al. 1999), the deple-
tion of glutathione and protein-bound sulf-
hydryl groups (Stohs and Bagchi 1995), the
production of inflammatory cytokines (Heo
et al. 1996), and the down-regulation of nitric
oxide production (Demontis et al. 1998; Vaziri
et al. 2001). Cadmium has also induced ather-
osclerosis and hypertension in some animal
models in vivo (Revis et al. 1981). However,
these mechanistic studies were typically con-
ducted at considerably higher exposures than
those corresponding to the urinary concentra-
tions observed in the present study, and hence
their relevance to human atherogenesis and to
PAD is uncertain.
Epidemiologic studies of cadmium and
cardiovascular disease are also limited.
Ecologic studies have found associations of
cardiovascular mortality rates with cadmium
levels in air (Carroll 1966) and in soil and
water (Houtman 1993). Two small case–
control studies found higher blood cadmium
Article | Navas-Acien et al.
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Figure 1. Metal levels in urine (µg/L) by participant characteristics. Horizontal lines, interquartile ranges; squares, medians; dotted vertical line, the geometric
mean for the overall study sample.
Overall
Men
Women
40–49 years of age
50–59 years of age
60–69 years of age
≥ 70 years of age
White
Black
Mexican American
Other
< High school
High school graduate
> High school
Never smoker
Former
Current
Cadmium Lead Barium Cobalt Cesium Molybdenum Antimony Thallium Tungsten
0.2 0.4 0.7 1.2 0.25 0.5 1.0 2.0 0.5 1.0 2.0 3.5 0.1 0.2 0.4 0.7 2.0 3.0 5.0 8.0 10 25 50 100 0.05 0.09 0.15 0.25 0.07 0.12 0.2 0.3 0.03 0.05 0.2 0.1
Metal levels (µg/L)
Table 2. Ratios (95% CIs) of the geometric means of metal levels in urine (µg/L) in PAD cases versus
noncases.
Cases Noncases Model 1a Model 2b Model 3c
Cadmium 49 679 1.81 (1.24–2.62) 1.62 (1.19–2.21) 1.36 (1.01–1.83)
Lead 54 736 1.09 (0.86–1.37) 1.08 (0.85–1.38) 0.92 (0.74–1.15)
Barium 45 659 0.99 (0.67–1.47) 0.99 (0.68–1.45) 0.82 (0.60–1.11)
Cobalt 54 736 1.13 (0.80–1.59) 1.13 (0.82–1.57) 0.98 (0.69–1.40)
Cesium 54 736 1.05 (0.83–1.32) 1.12 (0.89–1.42) 0.96 (0.79–1.16)
Molybdenum 49 679 0.97 (0.66–1.42) 1.08 (0.74–1.57) 0.91 (0.72–1.15)
Antimony 49 676 1.18 (0.92–1.51) 1.17 (0.92–1.50) 1.03 (0.87–1.22)
Thallium 54 722 0.97 (0.71–1.34) 1.08 (0.78–1.48) 0.94 (0.74–1.19)
Tungsten 51 700 1.75 (0.98–3.10) 1.67 (0.96–2.89) 1.49 (0.90–2.49)
aAdjusted by age, sex, race, and education. bFurther adjusted by smoking status (never/former/current). cFurther adjusted
by urinary creatinine.in subjects with myocardial infarction than in
controls (Adamska-Dyniewska et al. 1982;
Ponteva et al. 1979), but a cross-sectional
study in Belgium found no association
between blood cadmium and the prevalence of
cardiovascular disease (Staessen et al. 1996).
Finally, several autopsy studies have found
associations between tissue cadmium levels and
atherosclerotic lesions (Aalbers and Houtman
1985; Voors et al. 1982). Additional studies,
particularly with a prospective design, are
needed to conﬁrm the role of cadmium in the
pathogenesis of PAD and to determine its role
in other cardiovascular end points.
Lead. Lead in urine was not associated with
PAD in this study. This result is in contrast to
the association observed between blood lead
and PAD in NHANES 1999–2000, where
blood lead levels were 14% higher in cases of
PAD than in noncases (Navas-Acien et al.
2004). This discrepancy could be related to the
fact that urinary lead levels in this population
were low and may have considerable ﬂuctua-
tions when evaluated in spot urine samples.
Under these conditions, urinary lead is consid-
ered a less reliable biomarker of exposure than
blood lead (ATSDR 1999b). Indeed, previous
cohort studies of lead and cardiovascular dis-
ease have used blood lead as the biomarker of
exposure. Blood lead was positively associated
with cardiovascular mortality in NHANES II
(Lustberg and Silbergeld 2002) and with coro-
nary heart disease incidence in Denmark
(Moller and Kristensen 1992), although an
earlier study in British men did not show an
association between blood lead and cardio-
vascular disease incidence (Pocock et al. 1988).
Several mechanisms support a role for lead in
atherosclerosis. Lead increases blood pressure
(Nawrot et al. 2002; Revis et al. 1981), and
experimental studies show that lead promotes
oxidative stress (Stohs and Bagchi 1995), stim-
ulates inflammation (Heo et al. 1996), and
induces endothelial damage (Vaziri et al. 2001).
The role of lead in the development of athero-
sclerosis, however, needs to be further investi-
gated in mechanistic studies at low levels
of exposure and in prospective studies in
humans using appropriate biomarkers of
chronic exposure.
Tungsten. Tungsten levels in urine were
49% higher in subjects with PAD than in
those without PAD. This analysis is among the
first to examine the role of tungsten in any
health status indicator, and it needs to be inter-
preted cautiously in the context of multiple
comparisons. Little is known regarding tung-
sten toxicity and carcinogenicity (ATSDR
2003), and there are insufficient data, either
from animal or human studies, on its cardio-
vascular effects (Lagarde and Leroy 2002). It is
known, however, that tungsten is throm-
bogenic and proinflammatory (Byrne et al.
1997). In fact, these properties have motivated
the clinical use of tungsten coils for the occlu-
sion of intracranial aneurysms, varicocele veins,
and other abnormal vascular connections
(Butler et al. 2000; Peuster et al. 2002). In
addition, tungsten may interfere with the bio-
logic effect of molybdenum, an essential trace
element that acts as cofactor in several proteins
(Johnson et al. 1974; Nell et al. 1980). For
instance, tungsten inhibits xanthine oxidase
(Johnson et al. 1974), an antioxidant molyb-
doenzyme with a role in endothelial dysfunction
(Berry and Hare 2004) and in the maintenance
of the vessel wall integrity.
Sources of tungsten exposure include occu-
pational use of tungsten inert gas, welding, and
Article | Metals and peripheral arterial disease
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Figure 2. Odds ratios of PAD by metal levels in urine. The curves are odds ratios adjusted for age, sex, race, education, smoking, and urinary creatinine based on
restricted cubic spline transformations. The reference value (odds ratio = 1) was set at the 10th percentile of the distribution for each metal. The bar histograms
represent the frequency distribution of each metal in the study sample. The tick marks at the bottom of the histogram represent the metal level of the cases of PAD.
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Table 3. Odds ratio (95% CIs) of PAD comparing the 75th with the 25th percentile of the metal distribution.
Cases Noncases Model 1a Model 2b Model 3c
Cadmium 49 676 2.67 (1.40–5.07) 2.14 (1.11–4.13) 3.05 (0.97–9.58)
Lead 54 736 1.17 (0.81–1.69) 1.17 (0.78–1.76) 0.89 (0.45–1.78)
Barium 45 659 1.02 (0.67–1.56) 1.07 (0.72–1.58) 0.88 (0.57–1.36)
Cobalt 54 736 1.21 (0.65–2.23) 1.22 (0.67–2.20) 1.01 (0.33–3.14)
Cesium 54 736 1.08 (0.73–1.60) 1.19 (0.78–1.80) 0.91 (0.33–2.48)
Molybdenum 49 679 0.98 (0.60–1.60) 1.10 (0.69–1.77) 0.83 (0.49–1.41)
Antimony 49 676 1.25 (0.93–1.68) 1.30 (0.95–1.77) 1.15 (0.81–1.63)
Thallium 54 722 0.96 (0.53–1.73) 1.18 (0.60–2.32) 0.87 (0.30–2.52)
Tungsten 51 700 2.45 (1.12–5.37) 2.23 (1.03–4.82) 2.25 (0.97–5.24)
aAdjusted by age, sex, race, and education. bFurther adjusted by smoking status (never/former/current). cFurther adjusted
by urinary creatinine.sometimes drinking water. The amounts of
tungsten in foods and in ambient air are gener-
ally unknown (ATSDR 2003). Urban settings
tend to have higher levels of tungsten in the air
because tungsten can be released from indus-
trial sources and waste incinerators (tungsten
ﬁlaments are used in incandescent light bulbs)
(ATSDR 2003). In response to the lack of
knowledge on the health effects of tungsten
exposure coupled with evidence of widespread
human exposure, the CDC/NCEH nominated
tungsten in 2002 to the National Toxicology
Program as a priority candidate for toxicologic
assessment (U.S. Department of Health and
Human Services 2003). Our ﬁndings suggest
that these studies should also include the
evaluation of the relationship of tungsten to
cardiovascular end points and its potential
mechanisms of action.
Antimony. For antimony, there was an
increase in the prevalence of PAD in subjects
with low levels compared with those at the
limit of detection, and the risk remained
increased > 0.1 µg/L. The general population
is exposed to antimony in food, in drinking
water, and in ambient air (ATSDR 1992a).
At levels found in antimony smelting plants,
antimony has been related to pneumoconiosis
and dermatitis (McCallum 1989). Although
antimony is a well-known toxic metal at
high doses, there is only one available study
of chronic antimony exposure and cardio-
vascular end points in humans (Schnorr et al.
1995). This study compared coronary mortal-
ity in Mexican-American antimony smelter
workers with other groups of workers, but the
ﬁndings were inconclusive. Interestingly, anti-
mony shares similar chemical and toxicologic
properties with arsenic (Gebel 1997), and
they are frequent coexposures (Gebel et al.
1998). Arsenic exposure has been associated
with PAD, and “blackfoot disease” is a classic
sign of high arsenic exposure (Carter et al.
2003; National Research Council 1999).
Unfortunately, arsenic levels were not meas-
ured in NHANES 1999–2000, and we can-
not discard the possibility that the observed
association between PAD and antimony was
due to arsenic coexposure. Further studies are
required on antimony and cardiovascular
end points.
Other metals. Barium, cobalt, cesium,
molybdenum, and thallium in urine were not
associated with PAD in this representative
sample of the U.S. population. Data on the
possible role of these metals in atherosclerosis
are scarce. Ecologic studies have found positive
associations with cardiovascular disease for
barium (Brenniman et al. 1979) and thallium
(Heim et al. 2002) and a negative association
for molybdenum (Guo et al. 1992). Thallium
is a poison at high dose (ATSDR 1992b). At
low dose, thallium is used in cardiac imaging
and thought to be relatively safe (Ranhosky
and Kempthorne-Rawson 1990). Cobalt expo-
sure in the hard metal industry results in car-
diomiopathy (Seghizzi et al. 1994), but no
information is available on its atherogenicity.
Limitations and strengths. Our analysis
was limited by a relatively small number of
cases, because NHANES 1999–2000 meas-
ured metals in urine in just one-third of sur-
vey participants. This sample size limited the
investigation of interactions (e.g., lead and
cadmium, or tungsten and molybdenum) and
makes it possible that we missed weak associa-
tions between some metals and PAD. At the
same time, our prior hypotheses regarding the
associations of cadmium and lead with PAD
were specific, but for the other metals our
analyses were exploratory and need to be con-
ﬁrmed in future studies.
Other limitations include the cross-
sectional design of the study, the possibility of
residual confounding by socioeconomic status
or urbanization, the use of a single measure-
ment of urinary metals, and the lack of 24-hr
urine collection to better account for short-
term variability in metal excretion and urine
dilution. To correct for urine dilution, we
adjusted for urinary creatinine. However,
creatinine in urine is a marker of both urine
dilution and creatinine production, and it is
associated with factors that affect production
such as sex, age, race, and muscle mass. The
adequacy of correcting for creatinine has been
questioned (Ikeda et al. 2003), and in fact the
Second National Report on Human Exposure
to Environmental Chemicals (NCEH 2003),
based on NHANES data, presented metal
concentrations in urine both ways, with and
without correction for urinary creatinine. In
our data, the ﬁndings using models with and
without adjustment for creatinine were simi-
lar and do not affect the conclusions.
Despite these limitations, this study is the
ﬁrst systematic investigation of a panel of met-
als in urine with PAD. The use of a represen-
tative sample of the U.S. population, rigorous
laboratory methods with extensive quality
control, and the availability of a standardized
procedure to measure ABI add to the strengths
of this study.
Conclusions
Urinary cadmium was strongly associated with
PAD in a representative sample of the general
U.S. population. This finding strengthens
similar results from a previous study in the
same population using blood cadmium as a
biomarker of exposure (Navas-Acien et al.
2004) and further supports a possible role for
cadmium in atherosclerosis. Tungsten was
associated with PAD throughout the range of
exposure, whereas antimony showed a positive
association at low levels that reached a plateau
> 0.1 µg/L. These associations need to be inter-
preted cautiously and require conﬁrmation in
future epidemiologic studies and supporting
evidence from mechanistic research. Finally, no
association between PAD and other metals in
urine (lead, barium, cobalt, cesium, molyb-
denum, and thallium) was evident at the levels
found in the general population. The observa-
tion of widespread exposure, particularly to
poorly studied metals such as tungsten and
antimony, supports further research on the role
of metals and PAD.
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